Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;48(3):2945-2956.
doi: 10.1007/s11033-021-06318-9. Epub 2021 Apr 1.

Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review

Affiliations
Review

Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review

Shruti Gupta et al. Mol Biol Rep. 2021 Mar.

Abstract

Increased deaths caused due to pancreatic cancer (PC) is drawing much attention towards an immediate need for therapeutics that could possibly control this disease and increase the patients' survival rate. Despite the long list of well-established chemotherapeutic drugs in several cancers none have proved to be efficient against PC, and the increasing chemoresistance to the gold standard drug gemcitabine calls a need to search for solutions in other categories of drug. To the rescue, antifungals have shown themselves to be effective against PC and can increase gemcitabine sensitivity against PC. In this mini-review, we reported how antifungals have targeted PC and helped to reduce its lethality. Additionally, it is emphasized that how the antifungals show new mechanisms that could be triggered by using either monotherapy or combination therapy of these antifungals with chemotherapeutic drugs in PC. Moreover it shows an approach of using other drugs with possible same or other mechanism to know their effect on PC.

Keywords: Antifungal; Chemoresistance; Drug repurposing; Gemcitabine; Pancreatic ductal adenocarcinoma.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R et al (2007) Global cancer facts and figures. American Cancer Society, Atlanta
    1. Wiest NE, Moktan VP, Oman SP, Chirilă RM (2020) Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 58(3):119–128. https://doi.org/10.2478/rjim-2020-0009 - DOI - PubMed
    1. Gašić U, Ćirić I, Pejčić T, Radenković D, Djordjević V, Radulović S et al (2020) Polyphenols as possible agents for pancreatic diseases. Antioxidants (Basel) 9(6):547. https://doi.org/10.3390/antiox9060547 - DOI
    1. Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H (2019) Chemoresistance in pancreatic cancer. Int J Mol Sci 20(18):4504 - DOI
    1. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV (2020) Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 12(2):173–181. https://doi.org/10.4251/wjgo.v12.i2.173 - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources